Humira(克隆氏症) - 預測與市場分析
Humira (Crohn's Disease) - Forecast and Market Analysis to 2022
|出版日期||內容資訊||英文 47 Pages
|Humira(克隆氏症) - 預測與市場分析 Humira (Crohn's Disease) - Forecast and Market Analysis to 2022|
|出版日期: 2014年01月31日||內容資訊: 英文 47 Pages||
The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira's Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.
Humira is a recombinant human IgG1 mAb that binds to TNF-α and blocks its interaction with p55 and p75 cell-surface receptors, which reduces inflammation and stops tissue destruction. It was the first fully-humanized mAb TNF inhibitor to enter the market for the treatment of CD in the US in 2007. It is considered a first-line biologic therapy option and is indicated for the treatment of adults with moderately to severely active disease who have had an inadequate response to conventional therapy, as well as for patients with a loss of response or intolerance to Remicade.